M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$54bndisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Apr 2024 | Model N | – | Vista Equity Partners | Acquisition | Completed | 1,250.0 | Vertical SaaS+1 | Jefferies (sell-side)Fenwick & West (sell-side)Kirkland & Ellis (buy-side)William Blair (buy-side) |
| Dec 2024 | Randlab Group | – | Animalcare Group | Acquisition | Completed | 74.3 | Healthcare+1 | Squire Patton Boggs (buy-side)Pitcher Partners (buy-side) |
| Jan 2025 | ImaginAb therapeutic candidates, biologics technology platform and research facility | ImaginAb | Telix Pharmaceuticals | Asset sale | Completed | 45.0 | Healthcare+1 | Jefferies (sell-side)Stifel (sell-side) |
| Feb 2025 | AdvanCell | – | SV Health Investors | Stake | Completed | – | Healthcare+1 | Johnson Winter Slattery (buy-side)Honigman (buy-side) |
| Feb 2025 | Mayne Pharma Group | – | Cosette Pharmaceuticals | Scheme | Withdrawn | 417.9 | Healthcare+1 | Jefferies (sell-side)Gilbert + Tobin (sell-side)Arnold & Porter (sell-side)Davis Wright Tremaine (sell-side)EY (sell-side)Deloitte (sell-side)Santander (buy-side)UBS (buy-side)Corrs Chambers Westgarth (buy-side)Ropes & Gray (buy-side) |
| Jun 2025 | InVetro | – | Animalcare Group | Stake | Announced | – | Healthcare+1 | Squire Patton Boggs (buy-side) |
| Jul 2025 | BD Biosciences & Diagnostic Solutions business | Becton, Dickinson and Company | Waters | Asset sale | Completed | 18,800.0 | Life Sciences+2 | Citi (sell-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Barclays (buy-side)Kirkland & Ellis (buy-side) |
| Aug 2025 | DBG Global Enterprises | – | BDT & MSD Partners | Stake | Announced | 1,039.4 | Healthcare+1 | MinterEllison (sell-side) |
| Aug 2025 | DBG Health | – | BDT & MSD Partners | Stake | Completed | 1,039.4 | Healthcare+1 | MinterEllison (sell-side)Allens (buy-side)Sidley Austin (buy-side) |
| Oct 2025 | SWK Holdings | – | Runway Growth Finance Corp. | Acquisition | Completed | 249.0 | Financial Services+1 | Keefe, Bruyette & Woods (sell-side)Goodwin (sell-side)Kroll (sell-side)Simpson Thacher & Bartlett (buy-side)Dechert (buy-side) |
| Oct 2025 | Sedarex | – | Biotron | Acquisition | Completed | 1.0 | Healthcare+1 | Peak Asset Management (buy-side) |
| Dec 2025 | Freenome Holdings | – | Perceptive Capital Solutions Corp | Merger | Completed | 725.0 | Diagnostics+2 | TD Securities (sell-side)Guggenheim Securities (sell-side)BTIG (sell-side)Goodwin (sell-side)Greenberg Traurig (sell-side)Richards, Layton & Finger (sell-side)H.C. Wainwright & Co. (sell-side)Jefferies (buy-side)Leerink Partners (buy-side)Cooley (buy-side)Ropes & Gray (buy-side)Maples Group (buy-side)Ogier (buy-side)Scalar (buy-side) |
| Dec 2025 | Generation Bio Co. | – | XRA 7 Corp. | Acquisition | Announced | – | Biotech+1 | TD Securities (sell-side)WilmerHale (sell-side)Gibson Dunn (buy-side) |
| Jan 2026 | BioRender | – | Dimension Capital | Stake | Announced | 900.0 | Software+2 | Sidley Austin (sell-side) |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Jan 2026 | Aktana | – | PharmaForceIQ | Asset sale | Announced | – | Healthcare Software+2 | Canaccord Genuity |
| Jan 2026 | Verana Health | – | – | Merger | Announced | – | Healthcare Software+2 | BofA Securities (sell-side)Wilson Sonsini Goodrich & Rosati (buy-side) |
| Jan 2026 | Cannatrek | – | Little Green Pharma | Scheme | Completed | – | Healthcare+1 | K&L Gates (sell-side)Intrinsic Partners (sell-side)RSM (sell-side)Hamilton Locke (buy-side)Canaccord Genuity (buy-side) |
| Jan 2026 | Ganymede | – | Apprentice.io | Acquisition | Announced | – | Software+1 | Cooley (buy-side) |
| Jan 2026 | StarLIMS | – | Turn/River Capital | Stake | Announced | – | Software+2 | |
| Feb 2026 | Dutscher Group | – | Vivo Capital | Acquisition | Announced | – | Life Sciences+1 | Sidley Austin (buy-side)Mayer Brown (buy-side) |
| Feb 2026 | Bruder Consulting & Venture Group | – | Dark Horse Consulting Group | Acquisition | Completed | – | Accounting, legal and consulting+1 | Goodwin (sell-side)Edgemont Partners (sell-side) |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Announced | – | Pharma Services+2 | Goodwin (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
| Mar 2026 | JSR Life Sciences chromatography business | JSR Life Sciences | MERCK KGaA | Asset sale | Completed | – | Life Sciences+1 | William Blair |
| Mar 2026 | UK Biocentre | – | Azenta UK | Acquisition | Completed | 26.9 | Life Sciences+1 | Deloitte (buy-side)Bird & Bird (buy-side) |
| Mar 2026 | Biocare Medical | – | Agilent Technologies | Acquisition | Announced | 950.0 | Diagnostics+1 | Sullivan & Cromwell (buy-side) |
| Mar 2026 | Stratis Group | – | Nexus Health | Acquisition | Announced | – | Accounting, legal and consulting+1 | Clearsight Advisors (sell-side)Pillsbury Winthrop Shaw Pittman (sell-side) |
| Apr 2026 | Thermo Fisher Scientific's microbiology division | Thermo Fisher Scientific | Astorg | Asset sale | Announced | 1,075.0 | Diagnostics+1 | Cravath, Swaine & Moore (sell-side)Perella Weinberg Partners (sell-side)Latham & Watkins (buy-side)Moelis & Company (buy-side) |
| Apr 2026 | Accessus Health | shareholders of Ecker + Ecker and Accessus Health | Athagoras | Acquisition | Announced | – | Accounting, legal and consulting+2 | Latham & Watkins (sell-side) |
| Apr 2026 | TriNetX | – | Regeneron Pharmaceuticals | Stake | Completed | – | Healthcare Software+2 | William Blair |
| Apr 2026 | Celerion | H.I.G. Capital affiliate | THL Partners | Acquisition | Announced | – | Pharma Services+2 | LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side) |
| Apr 2026 | EpiVax | – | SV Health Investors | Acquisition | Announced | – | Pharma Services+2 | Morgan Lewis (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| May 2026 | Regenity Biosciences | – | Cinven | Stake | Announced | – | Medtech+1 | Baird (sell-side) |
| May 2026 | Beacon | Hanson Wade Group | Corten Capital | Acquisition | Announced | – | Market Intelligence+2 | Baird (sell-side) |
| May 2026 | Imexpharm | SK Group | Lian SGP Holding | Acquisition | Announced | – | Healthcare+1 | Allens (sell-side)Linklaters (sell-side) |
| May 2026 | Sutter Instrument Corp. | – | Lafayette Instrument | Acquisition | Completed | – | Manufacturing+2 | EC M&A (sell-side)Donahue Fitzgerald (sell-side)Akerman (buy-side)RSM (buy-side) |
| May 2026 | Ennov Group | – | Bregal Sagemount | Stake | Announced | – | Healthcare Software+2 | Proskauer RoseGoodwin (buy-side) |
| Jun 2026 | Aspen Pharmacare Asia Pacific business | Aspen Pharmacare Holdings | BGH Capital | Acquisition | Announced | 1,632.2 | Healthcare+1 | Allens (buy-side) |
| Jun 2026 | Kalderos | – | Model N | Acquisition | Announced | – | Healthcare Software+2 | Kirkland & Ellis (buy-side) |
| Jun 2026 | kneat.com | – | Thoma Bravo, L.P. | Acquisition | Pending | 453.6 | Vertical SaaS+1 | Kirkland & Ellis (buy-side) |
| Jun 2026 | Helio Health Group | – | WestView Capital Partners | Stake | Completed | – | AI+1 | Latham & Watkins (buy-side) |
| Jun 2026 | Ignite Proteomics | Aditxt | Proposed Ignite Proteomics Inc. holding company | Merger | Pending | 150.0 | Life Sciences+2 | Ladenburg Thalmann |
| Jun 2026 | Simulations Plus | – | Affiliates of Altaris | Acquisition | Announced | 375.0 | Life Sciences+2 | Morgan Stanley (sell-side)Procopio, Cory, Hargreaves & Savitch (sell-side)Bass, Berry & Sims (buy-side)Truist Securities (buy-side)J.P. Morgan (buy-side)Kirkland & Ellis (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Bio-Techne | – | Merck KGaA | Acquisition | Pending | 11,300.0 | Life Sciences+1 | Goldman Sachs (sell-side)Sidley Austin (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Guggenheim Securities (buy-side)J.P. Morgan (buy-side)Sullivan & Cromwell (buy-side) |
| Jul 2026 | GBA Group | Ardian | Bridgepoint | Acquisition | Announced | – | Testing & Inspection+1 | Latham & Watkins (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.